Renalytix (RENX) Proxy Filing summary

Executive summary

• The 2024 Annual General Meeting (AGM) will be held in December 2024 in London, with both ordinary shareholders and ADS holders eligible to vote on key resolutions electronically or by proxy.

• The Board unanimously recommends voting in favor of all resolutions, which cover financial, governance, and compensation matters.

• Voting results and AGM outcomes will be published on the company website and via regulatory filings.

Voting matters and shareholder proposals

• Nine resolutions are up for vote: adoption of annual accounts, approval of the directors' remuneration report, ratification of auditors, authorization of share allotment, disapplication of pre-emption rights, share repurchases, and equity incentive plan changes.

• All resolutions are recommended by the Board, with ordinary resolutions requiring a simple majority and special resolutions requiring 75% approval.

• Shareholders can submit proposals for the 2025 AGM, subject to regulatory and timing requirements.

Board of directors and corporate governance

• The Board consists of six directors with diverse backgrounds in life sciences, finance, and innovation, and includes both executive and independent members.

• The Board separates the roles of CEO and Chairman to reinforce independent oversight.

• Three standing committees (Audit, Remuneration, Nomination) are composed entirely of independent directors.

• Board diversity is tracked, and director nominations are open to shareholder recommendations.